Literature DB >> 24176497

Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.

Hiten D Patel1, Eric T Roberts, Dagna O Constenla.   

Abstract

BACKGROUND: Rotavirus gastroenteritis places a significant health and economic burden on Pakistan. To determine the public health impact of a national rotavirus vaccination program, we performed a cost-effectiveness study from the perspective of the health care system.
METHODS: A decision tree model was developed to assess the cost-effectiveness of a national vaccination program in Pakistan. Disease and cost burden with the program were compared to the current state. Disease parameters, vaccine-related costs, and medical treatment costs were based on published epidemiological and economic data, which were specific to Pakistan when possible. An annual birth cohort of children was followed for 5 years to model the public health impact of vaccination on health-related events and costs. The cost-effectiveness was assessed and quantified in cost (2012 US$) per disability-adjusted life-year (DALY) averted and cost per death averted. Sensitivity analyses were performed to assess the robustness of the incremental cost-effectiveness ratios (ICERs).
RESULTS: The base case results showed vaccination prevented 1.2 million cases of rotavirus gastroenteritis, 93,000 outpatient visits, 43,000 hospitalizations, and 6700 deaths by 5 years of age for an annual birth cohort scaled from 6% current coverage to DPT3 levels (85%). The medical cost savings would be US$1.4 million from hospitalizations and US$200,000 from outpatient visit costs. The vaccination program would cost US$35 million at a vaccine price of US$5.00. The ICER was US$149.50 per DALY averted or US$4972 per death averted. Sensitivity analyses showed changes in case-fatality ratio, vaccine efficacy, and vaccine cost exerted the greatest influence on the ICER.
CONCLUSIONS: Across a range of sensitivity analyses, a national rotavirus vaccination program was predicted to decrease health and economic burden due to rotavirus gastroenteritis in Pakistan by ~40%. Vaccination was highly cost-effective in this context. As discussions of implementing the intervention intensify, future studies should address affordability, efficiency, and equity of vaccination introduction.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; DALYs; DPT3; EMR; Eastern Mediterranean region; GAVI; GDP; Gastroenteritis; Global Alliance for Vaccines and Immunization; ICER; PATH; Pakistan; Program for Appropriate Technology in Health; RVGE; Rotavirus; Vaccination; WHO; World Health Organization; disability-adjusted life-years; final dose of diphtheria, pertussis, and tetanus vaccination; gross domestic product; incremental cost-effectiveness ratio; rotavirus gastroenteritis

Mesh:

Substances:

Year:  2013        PMID: 24176497      PMCID: PMC3865920          DOI: 10.1016/j.vaccine.2013.10.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Burden of rotavirus disease in European Union countries.

Authors:  Montse Soriano-Gabarró; Jacek Mrukowicz; Timo Vesikari; Thomas Verstraeten
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

2.  Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.

Authors:  Lara J Wolfson; François Gasse; Shook-Pui Lee-Martin; Patrick Lydon; Ahmed Magan; Abdelmajid Tibouti; Benjamin Johns; Raymond Hutubessy; Peter Salama; Jean-Marie Okwo-Bele
Journal:  Bull World Health Organ       Date:  2008-01       Impact factor: 9.408

3.  The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.

Authors:  Joseph Cook; Marc Jeuland; Dale Whittington; Christine Poulos; John Clemens; Dipika Sur; Dang Duc Anh; Magdarina Agtini; Zulfiqar Bhutta
Journal:  Vaccine       Date:  2008-10-07       Impact factor: 3.641

4.  Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.

Authors:  K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

Review 5.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

6.  WHO estimates of the causes of death in children.

Authors:  Jennifer Bryce; Cynthia Boschi-Pinto; Kenji Shibuya; Robert E Black
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

7.  Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment.

Authors:  M A Khan; J D Walley; S N Witter; A Imran; N Safdar
Journal:  Health Policy Plan       Date:  2002-06       Impact factor: 3.344

8.  Health and economic impact of rotavirus vaccination in GAVI-eligible countries.

Authors:  Sun-Young Kim; Steve Sweet; David Slichter; Sue J Goldie
Journal:  BMC Public Health       Date:  2010-05-14       Impact factor: 3.295

9.  Population-based surveillance for severe rotavirus gastroenteritis in children in Karachi, Pakistan.

Authors:  Romena Qazi; Shazia Sultana; Shiyam Sundar; Haider Warraich; Tayyab un-Nisa; Abida Rais; Anita K M Zaidi
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

10.  Multicenter, hospital-based surveillance of rotavirus disease and strains among indian children aged <5 years.

Authors:  Gagandeep Kang; Rashmi Arora; Shobha D Chitambar; Jagdish Deshpande; M D Gupte; Madhuri Kulkarni; Trilok N Naik; Dipali Mukherji; S Venkatasubramaniam; Jon R Gentsch; Roger I Glass; Umesh D Parashar
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

View more
  7 in total

Review 1.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

2.  Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.

Authors:  Abdur Razzaque Sarker; Marufa Sultana; Rashidul Alam Mahumud; Robert Van Der Meer; Alec Morton
Journal:  Hum Vaccin Immunother       Date:  2017-12-12       Impact factor: 3.452

3.  Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries.

Authors:  Sabbir Haider; Usa Chaikledkaew; Montarat Thavorncharoensap; Sitaporn Youngkong; Md Ashadul Islam; Ammarin Thakkinstian
Journal:  Open Forum Infect Dis       Date:  2019-03-08       Impact factor: 3.835

4.  Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.

Authors:  Abdulrazaq G Habib; Mohammed Lamorde; Mahmood M Dalhat; Zaiyad G Habib; Andreas Kuznik
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

Review 5.  QALY league table of Iran: a practical method for better resource allocation.

Authors:  Reza Hashempour; Behzad Raei; Majid Safaei Lari; Nasrin Abolhasanbeigi Gallezan; Ali AkbariSari
Journal:  Cost Eff Resour Alloc       Date:  2021-01-13

6.  Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa.

Authors:  Muhammad Hamza; Maryam A Idris; Musa B Maiyaki; Mohammed Lamorde; Jean-Philippe Chippaux; David A Warrell; Andreas Kuznik; Abdulrazaq G Habib
Journal:  PLoS Negl Trop Dis       Date:  2016-03-30

7.  The Scientific Basis and Advantage of Human Experiential Assessment in the quality control of Chinese Herbal Medicines exampling as Schisandrae Chinensis Fructus.

Authors:  Yongfeng Zhou; Dingkun Zhang; Haotian Li; Haizhu Zhang; Jixiang Fang; Yanqin Ma; Ping Zhang; Jiabo Wang; Xiaohe Xiao
Journal:  Sci Rep       Date:  2018-04-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.